Edited by Robert Langer, Massachusetts Institute of Technology, Cambridge, MA, and approved March 7, 2014 (received for review February 13, 2014) Large soft tissue defects involve significant tissue loss, requiring surgical reconstruction. Autologous flaps are occasionally scant, demand prolonged transfer surgery, and induce donor site morbidity. The present work set out to fabricate an engineered muscle flap bearing its own functional vascular pedicle for repair of a large soft tissue defect in mice. Full-thickness abdominal wall defect was reconstructed using this engineered vascular muscle flap. A 3D engineered tissue constructed of a porous, biodegradable polymer scaffold embedded with endothelial cells, fibroblasts, and/or myoblasts was cultured in vitro and then implanted around the femoral artery and veins before being transferred, as an axial flap, with its vascular pedicle to reconstruct a fullthickness abdominal wall defect in the same mouse. Within 1 wk of implantation, scaffolds showed extensive functional vascular density and perfusion and anastomosis with host vessels. At 1 wk posttransfer, the engineered muscle flaps were highly vascularized, were well-integrated within the surrounding tissue, and featured sufficient mechanical strength to support the abdominal viscera. Thus, the described engineered muscle flap, equipped with an autologous vascular pedicle, constitutes an effective tool for reconstruction of large defects, thereby circumventing the need for both harvesting autologous flaps and postoperative scarification.
tissue engineering | vascularization | reconstructive surgery | tissue regeneration S uccessful restoration of substantial large soft tissue defects, caused by severe trauma or cancer ablation, poses a significant clinical challenge (1) . The current therapeutic approach involves grafts, synthetic material replacement, and autologous tissue transfer by means of tissue flaps. Tissue grafts are ineffective in repairing large defects (2) because of the absence of blood supply, and they resorb or necrose when postimplantational vascularization is not established (3) (4) (5) . In contrast, flaps are autologous tissues that can be transferred with their own blood supply and therefore, preferred for repair of large defects. However, the duration of the surgical operation, the scant availability of quality vascularized flaps, and donor site morbidity often limit their use (6) .
In recent years, the tissue engineering discipline has presented a promising approach to address these challenges by providing new sources of tissues and enabling angiogenesis into the tissue after implantation (3) . Numerous works report successful generation of tissue for repair of a variety of tissue defects, such as breast reconstruction with adipose tissue (7, 8) , and various aesthetic restorations in the face and the body (9) (10) (11) (12) . Successful transplantation of tissue-engineered trachea (13, 14) and bladder (15) was reported in human patients, and encouraging results were observed on transplantation of a variety of tissues, such as cornea (16) , bone (17) , and skin (18) . However, although this approach provides a successful platform for mass generation and transplantation of thin tissues, fabrication of a thick vascularized engineered tissue bearing its own pedicle still remains an unmet challenge of tissue engineering.
The purpose of this study was to fabricate an engineered muscle flap for repair of large soft tissue defects in mice, whereas large abdominal wall defects were chosen as a proof-of-concept model. A muscle tissue was constructed in vitro by seeding myoblasts, fibroblasts, and endothelial cells onto a 3D biodegradable poly-L-lactic acid (PLLA)/poly(lactic-coglycolic acid) (PLGA) scaffold. The graft was cultured in vitro until a small capillary net was formed, which was then anastamosed in vivo with the capillaries sprouted from the recipient's femoral artery and vein. The graft was then transferred with the femoral vessels, as a flap, to cover a full-thickness abdominal wall defect. The transferred flap proved viable and well-vascularized, provided mechanical support to the abdominal wall, and became well-integrated in the surrounding tissue. Thus, the engineered tissue flap, bearing both host and human-derived blood vessels, presents a novel tool for repairing a full-thickness defect of the abdominal wall without requiring autologous muscle flap.
Results
Postimplantational viability of a large and thick engineered tissue requires nutritional support that can only be provided by a large blood vessel. For this purpose, grafts constructed of a porous, biodegradable PLLA/PLGA scaffold embedded with endothelial cells (ECs), fibroblasts, and/or myoblasts (Fig. 1A) were cultured for 10 d and then folded around the host's artery and vein (AV) while being separated from the surrounding tissue by a piece of sterile latex ( Fig. 1 B and E-I). One and two weeks postimplantation, the graft with the AV was transferred to the abdominal full-thickness wall defect as an axial flap ( Fig. 1 C, D , and J-N).
Significance
Effective restoration of large soft tissue defects requires the use of tissue flaps, with viability that is largely determined by degree of vascularization. In view of the tedious transfer procedures and donor site morbidity associated with autologous flaps, this work set out to design and evaluate an engineered muscle flap featuring a robust vascular port formed from preseeded endothelial cells and host vasculature. The implanted flap was highly vascularized, well-perfused, and anastomosed with host vessels. Engineered flaps of this nature promise to circumvent the need to harvest and transfer massive tissue volumes, while avoiding the consequential complications.
Analysis of Graft Integration and Vascularization. Three types of fabricated grafts were prepared consisting of (i) myoblasts (Myo graft), (ii) ECs and fibroblasts (EC/Fib graft), or (iii) ECs, fibroblasts, and myoblasts (EC/Fib/Myo graft), and they were designed to most closely mimic the composition of a muscle tissue. An empty scaffold was used as a control. The viability and vascularization of the grafts were assessed 1 and 2 wk after implantation.
Macroscopically, within 1 wk of implantation, all grafts appeared viable and had already become vascularized (Fig. 1J) , and new functional blood vessels had sprouted from the AV to the engineered tissue graft (Fig. 2 A-D) . Many capillaries were observed in the tissue surrounding the AV, suggesting that the scaffolds had integrated with the host tissue. EC/Fib/Myo grafts were most highly vascularized, which was indicated by the mean vasculature density of CD31-positive vessels per millimeters 2 ( Fig. 2E and Fig. S1 ) and significantly higher than that observed in the Myo, EC/Fib, and empty grafts (Fig. 2 G-I) . At 2 wk postimplantation, both the EC/Fib/Myo and Myo grafts were highly vascularized, with similar densities of CD31-positive vessels ( Fig. 2F ) and no significant differences seen when using either C2C12 myoblasts or primary myoblasts (Fig. S2A) . In contrast, vascularization of the EC/Fib and empty grafts remained low (Fig. 2F ).
An i.v. injection of a mixture of Ulex europaeus agglutinin I and Griffonia simplifolia isolectin B4 was administered to determine whether the vascular network of the engineered tissue graft had anastomosed with host vessels and identify perfused and functional blood vessels (19, 20) . Two patterns of double staining confirmed perfusion within the vessels and included either human umbilical vein endothelial cells (HUVECs) wrapped around host blood vessels or long human-derived vessels that had anastomosed with host blood vessels ( Fig. 2 J and K) . Most of the blood vessels found in the graft area were mouse-derived vessels.
Analysis of Graft Perfusion and Vascularization. Vessel patency and the extent of vascularization and neovasculature within the grafts were assessed by injection of FITC-Dextran into the tail vein and analysis of the functional vessel density (FVD) from confocal images of the graft areas ( Fig. 3 A-C and Movie S1, Doppler). One week after implantation, the FVD of the EC/Fib/Myo grafts was markedly higher than that of both the Myo and EC/Fib grafts ( Fig. 3 A, a-c ; B, a-c; C, a-c; and D and Fig. S2B ). However, 2 wk after implantation, the FVD of Myo and EC/Fib/Myo grafts was similar, whereas the FVD of the EC/Fib grafts remained stable (Fig. 3 A, d-f ; B, d-f; C, d-f; and E).
Ultrasonigraphic evaluation of graft perfusion rate and the perfused vascular volume showed perfusion within the EC/Fib/Myo grafts at 1 and 2 wk postimplantation, which was expressed by the low number of orange pixels within the graft immediately after the disruption pulse of the microbubbles (outlined in Fig. 4A ) and a signal increase 25 s later (Fig. 4 B and C, EC/Fib/Myo grafts and Movie S2). At 1 wk postimplantation, both the perfusion rate and the perfused vascular volume within EC/Fib/Myo grafts were higher than those of the Myo and EC/Fib grafts ( Fig.  4 D and E). At 2 wk after implantation, the perfused vascular volume in the EC/Fib/Myo and Myo was higher compared with immediately after the disruption pulse and significantly higher than in EC/Fib grafts, suggesting that the presence of myoblasts promotes graft vasculogenesis. Despite this improved perfused vascular volume, the perfusion rates in the three types of grafts did not significantly differ from one another at this time point (Fig. 4 F and G) .
Flap Transfer and Macroscopic Analysis of the Transferred Flap. We next assessed the viability of the flaps after their transfer to a fullthickness defect in the abdomen ( Fig. 1 J and K) . One week after their transfer, flaps derived from cell-populated scaffolds were viable, which was evidenced by their red color (Fig. 1L ). In contrast, empty scaffolds became necrotic ( Fig. 1 M and N) and in some instances, led to animal death because of herniation of the abdominal organs.
Because most of the functional blood vessels in the transferred flap were of mouse origin, we next determined the extent of flap vascularization by means of murine CD31 staining. Murine CD31-and H&E-stained flap sections revealed the presence of many capillaries within the flaps ( (Fig. S3 A, a-c and g-i and B, a-c and g-i). In the EC/ Fib flaps, desmin-stained fibroblasts, which had differentiated into smooth muscle cells, were located around CD31-positive vessels (Fig. S3 A, g and B, g ). MT-stained sections of all flaps transferred 1 wk after graft implantation included myogenic cells at the flap edges proximal to the host tissue (Fig. S3A, a-c) . Examination of the desmin-stained Myo and EC/Fib/Myo flaps transferred at 1 wk postimplantation revealed the presence of myogenic cells also in the center of the flap (next to its vasculature) (Fig. S3A, g-i) . Although most of these myogenic cells were young myoblasts originating from either seeded myoblasts or invading host cells, elongated and aligned myocytes were also observed (Fig. S3 A, h and i and B, h and i). Moreover, most of the myogenic cells in the EC/Fib/Myo flaps were aligned and elongated (Fig. S3A, i) . Examination of the MT-and desmin-stained sections of Myo flaps transferred 2 wk after graft implantation revealed the presence of aligned and elongated myoblasts (Fig.  S3B, h ). In the EC/Fib/Myo flaps, mature myocytes, were observed (Fig. S3B, i) , suggesting more efficient integration of EC/Fib/Myo flaps with the host tissue than in other flap types.
Mechanical Flap Properties. During flap extraction attempts 1 wk posttransfer, EC/Fib/Myo flaps showed firm attachment to the surrounding tissue compared with the control groups. In EC/Fib/Myo flap extraction attempts, wound dehiscence did not occur (zero of six), whereas it occurred in 75% of the extraction attempts of the other tested flaps (four of six in Myo flaps and five of six in EC/Fib flaps) and 100% of the attempts made with control grafts (eight of eight). The engineered flaps were then compared with empty and EC/Fib/Myo control grafts. Hernia was only observed when extracting the empty (three of three) and EC/Fib/Myo grafts (four of five). Evaluation of the tensile strength of the flaps (Fig. 6 A and B) showed that flaps derived from EC/Fib/Myo scaffolds bore the highest tensile strength (Fig. 6C ). Myo flap stiffness was greater than that of flaps derived from the empty scaffolds but less than that of EC/Fib flaps (Fig. 6C) . Similarly, the highest ultimate tensile strength (UTS) was measured for EC/Fib/Myo flaps, whereas flaps derived from empty scaffolds yielded the lowest UTS (Fig. 6D) . Myo flaps featured a higher UTS than EC/Fib flaps. Overall, these results suggest that the presence of endothelial cells and myoblasts in the flaps is critical for the final strength and stiffness of the fabricated tissue.
Discussion
Reconstruction of complex large soft tissue defects caused by trauma or tumor ablation presents major clinical challenges. Although a wide variety of biological (21-23) and synthetic (1, 24, 25) matrices have been evaluated for their efficacy in tissue repair, their use is limited because of the lack of a blood supply, leading to their necrosis, infection, or possible rejection. In parallel, contemporary surgical techniques exploiting local, regional, or free flaps present disadvantages, such as donor site morbidity, procedure duration, the often scant availability of tissues in the area of the defects, and a requirement for higher surgical skill.
In our previous work (26), we showed that abdominal muscle injuries can be treated using grafts seeded with tricultures of ECs, fibroblasts, and myoblasts. In the present study, we expand the technique to treat large soft tissue defects when skin coverage is inadequate and grafts are ineffective using an engineered tissue with its pedicle. We designed and investigated a novel method for repair of a large soft tissue defect, where an abdominal full-thickness defect was used as a proof of concept using an engineered vascularized flap. The prefabricated graft, implanted around the AV, proved viable, vascularized, and perfused, and it contained blood vessels that anastomosed with host blood vessels. After transfer of the flap to the abdominal wall full-thickness defect, the engineered tissue sample remained viable and vascularized and became well-integrated within the surrounding tissue. EC/Fib/Myo scaffold-derived flaps outperformed all other flap types in their degree of vascularization, perfusion, mechanical properties, and tissue integration within the host. Thus, use of an engineered tissue with a functional blood vessel network can circumvent the need for transfer of massive tissue volumes from another site and avoids postoperative scarification of the donor site.
Proper flap vascularization is essential for its successful integration within the host (24, 25, 27) . Various approaches have been used to create vascularized engineered tissue to improve oxygen supply and diffusion in thick tissues. Sekine et al. (28) proposed in vitro fabrication of cardiac tissue with perusable blood vessels using a muscle tissue with a connectable artery and vein as a bed perfused in a bioreactor. Dvir et al. (29) constructed a vascularized cardiac patch using both survival and angiogenic factors by first implanting the patch on the omentum. Controlled delivery of proangiogenic factors from growth factoreluting scaffolds has been shown to induce host vessel ingrowth into the implant (30), whereas EC seeding has been attempted to promote additional vascularization on implantation (31) . We have previously shown that the postimplantational vascularization of a scaffold preseeded with ECs and tissue-specific cells was greater than that of EC-free scaffolds and correlated with improved integration within the host tissues (26, (32) (33) (34) (35) . We have also previously achieved repair of small abdominal defects using an engineered tissue graft derived from a scaffold seeded with HUVECs, fibroblasts, and myocytes (26) . However, when fabricated with a viable blood vessel network, larger quantities of tissue and even a whole organ can be implanted and then coupled to the main vessel trunk by attaching the blood vessel network of the engineered tissue to host vessels. The extensive vascularization and perfusion observed in Myo grafts stands in line with previous reports of secretion of angiogenic factors (including VEGF) by C2C12 cells, which in turn, stimulate vascularization of the surrounding tissue (36, 37) . The FVD of Myo grafts, which was higher than that of EC/Fib grafts, was seemingly a result of the large number of small and immature blood vessels, which may have been induced by C2C12-derived angiogenic factors. In parallel, ECs and fibroblasts have also been reported to secrete VEGF (38, 39) . In line with these works, the addition of ECs significantly promoted flap vascularization and viability after transfer. We showed that the ECdependent blood network generated in vitro was functional and integrated with the host vessels on implantation. The EC/Fib/Myo flap underwent the most effective integration and induced the most advanced regeneration of host tissue compared with the other tested flaps. Additional investigation will be necessary to uncover the main role of ECs in viability and integration of engineered tissues (particularly, to determine to what extent the ECs physically participate in blood vessel network formation in vivo and if their impact is primarily through secretion of VEGF and other growth factors after graft transfer) (40) .
The presented work shows that the cell types integrated in the engineered flaps dictate their mechanical strength. Specifically, EC/Fib/Myo flaps were stiffer and stronger than EC/Fib, Myo, and empty flaps. We also observed that, during manual flap extraction attempts, wound dehiscence did not occur in mice treated with the EC/Fib/Myo flaps, whereas it often occurred to animals treated with other flaps, which we attribute to the increased mechanical strength of the transplanted tissue (41) .
The correlation between secretion of VEGF, a key regulator of myoblast differentiation and function (42, 43) , and myoblast maturation has been previously reported (40) . When myotubes are formed, the myocytes become vascularized and innervated and finally, mature as myofibers, which are then packed together by connective tissue to provide mechanical strength to the muscle (40, (44) (45) (46) . Muscle cell alignment and elongation are crucial steps in muscle regeneration, where the final strength of muscle tissue is derived from the parallel organization of the myotubes within the muscle tissue. It has also been shown that vascularization of skeletal muscle is essential for muscle regeneration (47, 48) . Indeed, we observed mature and aligned myoblasts in the EC/Fib/Myo flaps, suggesting a mechanism that supports more rapid muscle regeneration.
The results of this study provide experimental evidence for the requirement of tissue-specific cells (i.e., myoblasts) as well as ECs and fibroblasts in successful muscle flap engineering. Furthermore, these results emphasize the need for functional vessels in flaps applied to large soft tissue defects. Specifically, we showed that EC/Fib/Myo flaps became more vascularized by host blood vessels and were more rapidly and more effectively integrated within the host tissue than EC/Fib or Myo flaps. The results of this study are sure to stimulate additional research in a large animal model and clinical studies in humans. In this regard, it is worth mentioning that, in larger animals and humans, other vessels commonly used for reconstruction in the clinic or even engineered large blood vessels can be used for generation of the vascular network of the engineered flap. In addition, the engineered flap can be transferred, as a free flap, to reconstruct defects in other areas of the body.
Materials and Methods
Detailed materials and methods are in SI Materials and Methods. Briefly, porous scaffolds were fabricated from 50% PLLA and 50% PLGA as previously described (35) . Three types of fabricated grafts were prepared by embedding scaffolds with (i) myoblasts (Myo graft), (ii) HUVECs and normal human dermal fibroblasts (EC/Fib graft), or (iii) HUVECs, normal human dermal fibroblasts, and myoblasts (EC/Fib/Myo graft). Ten days postseeding, mice were anesthetized by an i.p. injection of a ketamine:xylazine (6:1) mixture. The femoral AV bundle was then exposed from the level of the inguinal ligament to the knee area. To preserve the blood flow, the profunda was left untouched. The graft was folded around the exposed femoral AV-below the profunda and above the bifurcation to the tibial and proneal AV-and its ends were joined using 8-0 silk sutures. To ensure implant vascularization by the femoral AV bundle only, a piece of sterilized latex was wrapped around the graft and secured with 8-0 silk sutures. The overlying skin was then closed using 4-0 silk sutures; 1-2 wk after graft implantation, the grafts were either harvested for analysis or transferred as flaps. The tissue flap was then carefully dissected from the surrounding tissues after removal of its latex cover. The distal ends of the femoral AV were ligated with 8-0 silk sutures and then cauterized at the level of the knee (distally to the folded implanted tissue). The femoral AV with the surrounding tissues was then transferred up as a flap to repair a full-thickness defect in the ventral abdominal wall, which was made, during the same procedure, by removing a 1.0 × 0.8-cm section of the rectus abdominus muscle, with the overlying skin. The flap was sutured to the surrounding muscle tissues using 8-0 silk sutures, and the wound was covered with iodinated gauze and a sterile plaster. The skin of the leg was closed using 4-0 silk sutures. All mice were closely monitored every day for 1 wk, after which time they were euthanized to allow for flap retrieval for tensile strength testing or histological or immunohistological analysis. HUVECs, and 0.2 × 10 6 NHDFs in 1:1 HUVEC:myoblasts medium] by growing each cell type separately in its respective medium and preparing each suspension by suspending the cells in a mixture of 4 μL Matrigel and 4 μL culture medium. Each cell suspension was then seeded onto the scaffold and allowed to solidify (30 min, 37°C, 5% CO 2 ) in a six-well plate. Cell-free grafts with or without Matrigel were used as controls. After solidification, culture medium (4 mL) was added to each well and replaced every other day for a period of 10 d.
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3. Graft Implantation. All animal studies were approved by the Committee on the Ethics of Animal Experiments of the Technion. For all animal-based determinations, athymic nude male mice (7-to 9-wk-old mice; Harlan Laboratories Inc.,) were randomly assigned to three or four groups of three to five mice per group. Before graft (i.e., 10-d-old cell-populated scaffolds) implantation, mice were anesthetized by an i.p. injection (35 μL/20 g) of a ketamine:xylazine (6:1) mixture. The femoral artery and vein (AV) bundle was then exposed from the level of the inguinal ligament to the knee area. To preserve the blood flow, the profunda was left untouched. The graft was folded around the exposed femoral AV (below the profunda and above the bifurcation to the tibial and proneal AV), and its ends were joined using 8-0 silk sutures. To ensure implant vascularization by the femoral AV bundle only, a piece of sterilized latex was wrapped around the graft and secured with 8-0 silk sutures. The overlying skin was then closed using 4-0 silk sutures. All mice were monitored closely until they recovered from the anesthesia and every day thereafter until the grafts were harvested for analysis or transferred as flaps.
4. Flap Transfer. Mice were anesthetized with the ketamine:xylazine mixture 1-2 wk after graft implantation. The tissue flap was then carefully dissected from the surrounding tissues after removal of its latex cover. The distal ends of the femoral AV were ligated with 8-0 silk sutures and then cauterized at the level of the knee distally to the folded implanted tissue. The femoral AV with the surrounding tissues was then transferred up as a flap to repair a full-thickness defect in the ventral abdominal wall, which was made during the same procedure by removing a 1.0 × 0.8-cm section of the rectus abdominus muscle with the overlying skin. The flap was sutured to the surrounding muscle tissues using 8-0 silk sutures, and the wound was covered with iodinated gauze and a sterile plaster. The skin of the leg was closed using 4-0 silk sutures. Cell-free and EC/Fib/Myo grafts were used as control groups. EC/Fib/Myo grafts were incubated for the whole period in vitro (24 d). In the control groups, the grafts were sutured to repair a full-thickness defect in the abdominal wall (as explained above) without transferring the femoral AV. All mice were closely monitored every day for 1 wk, after which time they were euthanized to allow for flap retrieval for tensile strength testing (see below) or histological or immunohistological analysis.
Determination of the Extent of Functional Graft Vascularization.
The extent of tissue graft vascularization was determined 1 and 2 wk after implantation. After anesthetization with ketamine and xylazine, 10 mg/mL FITC-Dextran (Sigma-Aldrich) was i.v.-injected into the tail vein. On completion of the injection, the mice were euthanized, and the graft was imaged using confocal microscopy. The grafts were then excised and transferred to 10% buffered formalin (Sigma-Aldrich) for histological or immunohistological analysis.
Vascularization was quantified using MATLAB (Mathworks). First, the green channel (excitation = 488 nm) of the confocal microscopic images was isolated. The resulting images were then passed through a high-pass filter to accentuate the high-contrast structures. Second, a despeckling filter was used to remove noise that might have been amplified by the high-pass filter. The resulting image was then thresholded using a predefined value; the threshold value was adjusted so that the features and structures in the original image were visible in the binary image. A size threshold was then applied so that only groups of connected pixels larger than the size threshold remained in the binary image. Finally, the skeleton of the vessels in the graft was outlined using Zhang-Suen's algorithm to determine the functional vessel density (FVD) in each graft. The FVD was calculated by summing the lengths of the midline of each vessel and dividing the result by the area of the region of interest (ROI).
6. Ultrasound Determination of Vascular Perfusion of the Graft. Before transfer, vascular perfusion of the graft was measured 1 and 2 wk after implantation by ultrasonography. For this purpose, mice were anesthetized using 2% isoflurane; animal body temperature was maintained using a movable heated stage (VisualSonics) with temperature that was set at 38°C. Patency of the femoral vessels was examined, and the grafts were first located using B-mode and color Doppler ultrasonography (Movie S1), with an MS250 nonlinear transducer (VisualSonics). Then, the Vevo Micromarker nontargeted contrast agent (microbubbles; VisualSonics) was injected into the tail vein. Images were captured in the nonlinear contrast mode of the Vevo 2100 high-resolution ultrasound system and analyzed using the Vevo 2100 software as described previously (2) . Briefly, an ROI was drawn on the graft's image that was obtained from B-and contrast-mode images that were captured immediately after a disruption pulse, which destroys all of the injected microbubbles. After the disruption pulse, the microbubbles refill the vessels at a rate that only depends on the flow rate of the microbubbles in the capillaries and is independent of the injection rate of the microbubbles. The peak enhancement is the ratio of the mean intensity of the nonlinear signal after the injection of the microbubbles vs. after the disruption pulse, and it is a measure of the perfusion volume. The flow rate can be determined from the time that elapses until the peak signal. Patency of the femoral vessels posttransfer was ensured using the Doppler mode.
Immunohistological and Histological Staining of the Grafts and
Flaps. Grafts were fixed in 10% neutral buffered formalin (SigmaAldrich) and embedded in paraffin using standard fixation and embedding procedures. The paraffin-embedded sections were then deparaffinized by immersion in 100% xylene and rehydrated by serial immersions in decreasing concentrations of ethanol. Standard protocols were used for H&E and Masson's trichrome staining of the paraffin-embedded sections. For immunohistological staining, the epitopes were recovered by heating the specimens in Vector antigen unmasking solution (Vector Laboratories). The activity of endogenous peroxidase was quenched by incubating the slides in 3.3% (vol/vol) H 2 O 2 solution in methanol for 10 min, rinsing in PBS, and then incubating in a 2% (vol/vol) goat serum blocking solution for 30 min at room temperature (RT). The slides were then incubated overnight at 4°C in an anti-CD31 antibody solution (1:50; Abcam), rinsed with PBS, incubated with a biotinylated secondary antibody (1:400; Vector Laboratories) for 30 min at RT, rinsed with PBS, and incubated with streptavidin-peroxidase (1:400; Vector Laboratories) for another 30 min at RT. The nuclei were stained in blue by immersing the sections in hematoxylin for 2 min. After gentle rinsing in water, the sections were covered with Vectamount mounting medium (Vector Laboratories). CD31 staining was visualized as a brown stain using the aminoethylcarbazole substrate kit (Invitrogen). CD31-positive staining was determined and quantified in a double blind analysis of five randomly selected areas within the graft observed at 40× magnification.
The tissues were harvested and fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for 1-2 h, incubated overnight in a 30% (wt/vol) sucrose solution, embedded in optimal cutting temperature compound (Tissue-Tec), and frozen for subsequent cryosectioning (5-7 μm). The sections were incubated in a 0.5% Tween solution for 20 min, rinsed with PBS, and then blocked with a 5% (wt/vol) BSA (Sigma-Aldrich) blocking solution for 30 min. The sections were then simultaneously incubated in an anti-CD31 antibody solution (1:200; BD Biosciences) and an antidesmin antibody solution (1:50; Santa Cruz Biotechnology, Inc.) for 30 min at RT before being thoroughly washed in PBS. The sections were then labeled with Alexa 488 and Alexa 532 dye conjugates of IgG (1:200; Jackson Immunoresearch Laboratories, Inc.). The slides were mounted in Vectashield that contained DAPI (Vector Laboratories) before being examined under a fluorescence microscope (Axiovert 200M; Zeiss) and a Leica TCS-LSI confocal microscope.
Determination of the Extent of Flap Vascularization and Vessel
Circumference. The extent of flap vascularization and vessel circumferences were determined by quantifying CD31 staining. For this purpose, flap cryosections were first immunostained for murine CD31, which was quantified using the tile function of the Leica TCS-LSI confocal microscope and a MATLAB code. The code first filtered the green (excitation = 488 nm) channel from the image to isolate the murine CD31 staining. An automatic image analysis process was then used to segment the blood capillaries in a given ROI and calculate the area and circumference of the segmented vessels. The image segmentation was performed as follows. Single images taken from the TIF stack sequence input, which was created by the confocal microscope's software, were first summed. Median image filtration was then applied to reduce noise before manual masking of the ROI. The resultant image was converted into a binary image, and Sobel edge filtering was applied to detect the edges of the capillaries. This image of the edges was segmented using morphological operators, which enhanced and connected the edges of the vessels. Dilation was used to intensify and connect the vessels, and a dilation operator was used to reduce noise and delete small pixel elements. The image, now showing only the intensified edges of the vessels, was analyzed using an eight-neighbor boundary detection algorithm that generated a single vector graphics representation for each closed vessel. The area and circumference of each vessel were calculated and written into a CSV text file, which was used for the final analysis. In this analysis, vessels with small lumens (circumference < 8 pixels) were categorized as noise and disregarded in the final analysis.
9. Determination of the Extent of Vascular Anastomosis. To distinguish between host vessels and the implanted HUVECs and determine whether the vessels had anastomosed, a mixture of rhodamine-labeled Ulex europaeus agglutinin I (Vector Laboratories) human-specific lectin and FITC-conjugated Griffonia simplifolia isolectin B4 (Vector Laboratories) murine-specific lectin were injected into the tail vein 1 wk after graft implantation using a previously described protocol (2) . Mice were euthanized 20 min after the injection, and the grafts were harvested, fixed in 10% buffered formalin for 2-4 h, incubated overnight in 30% (wt/vol) sucrose, embedded in optimal cutting temperature compound, frozen, and cryosectioned into 60-μm sections for confocal imaging. 10 . Tensile Testing of the Flaps. A stress-strain curve was generated using the Biodynamic test instrument (Bose Corporation) under a strain rate of 0.01 mm/s until failure. Stress was calculated as the measured force divided by the cross-sectional area of the flap, and strain was calculated as elongation divided by the flap's initial length. The flap's stiffness was calculated as the slope of the linear region of the stress-strain curve, and the maximum point of the curve was deemed to be the ultimate tensile strength (3). For these determinations, the flaps were retrieved 7 d after transfer, and their dimensions were obtained while they were maintained in PBS and immediately after mounting them onto the system's grips.
11. Statistical Analysis. All data were statistically analyzed by a oneway ANOVA followed by a posthoc Student Newman-Keuls multiple comparisons test using a computerized statistical program (InStat; GraphPad Software, Inc.). Statistical significance was set at 5%, and all results are presented as mean ± SEM. 
